Patient Guide · Lu-177 Therapy
Your doctor has offered youLu-177 therapy.Here's what it involves.
Lu-177 (lutetium-177) therapy is a targeted radionuclide treatment — a radioactive medicine that is drawn to the surface of specific cancer cells and delivers its radiation dose there, not to your whole body. In India it is used for two main indications: neuroendocrine tumours(Lu-177 DOTATATE, also called PRRT) andadvanced prostate cancer(Lu-177 PSMA-617). This page walks you through what the treatment day is like, how to prepare, and the radiation-safety steps that protect your family for the first few days after each cycle. Written for patients and their families, not for clinicians.
Important: this page is educational. It does not replace the specific advice of your nuclear-medicine physician, oncologist and treating team, who know your medical history, imaging and dose plan. Always follow their instructions in preference to anything on this page.
What is Lu-177 therapy?
Radiation delivered to your cancer, not your whole body
A radioactive medicine delivered to your tumour, not your whole body
Lu-177 therapy is what doctors call "targeted radionuclide therapy" or "theranostic therapy". A small amount of radioactive lutetium-177 is chemically attached to a molecule (DOTATATE or PSMA-617) that is drawn to specific proteins on the surface of cancer cells. When the medicine is given as an IV infusion, it circulates through your body but concentrates in the cancer — delivering its radiation dose there, not to healthy organs. Because the radiation acts only over about 2 mm of tissue, the effect is highly targeted.
Different from chemotherapy
Chemotherapy uses drugs that damage rapidly-dividing cells throughout the body — that is why hair loss and severe nausea are common. Lu-177 therapy uses radiation delivered by a targeting molecule; most patients feel much better on Lu-177 than on chemotherapy. Fatigue and mild nausea are common; severe side effects are uncommon.
Different from external-beam radiotherapy
External-beam radiotherapy uses a linear accelerator to aim radiation at your body from outside. Lu-177 therapy delivers the radiation from inside — you become a temporary source of very low-level radiation for a short period after the infusion. The radiation-safety precautions below are about protecting the people around you for those first few days.
Who receives Lu-177 therapy
Two main indications in Indian centres
Lu-177 DOTATATE (PRRT)
Adults with metastatic or unresectable well-differentiated neuroendocrine tumours (NETs) — most commonly midgut / gastroenteropancreatic NETs and lung NETs that express somatostatin receptor 2 on their surface.
How you're selected
Selected using a Ga-68 DOTATATE PET/CT scan — if your tumours light up on that scan, the same targeting molecule (labelled with therapeutic Lu-177 instead of imaging Ga-68) can deliver treatment to them.
Typical course
Typically 4 cycles, 8 weeks apart. Each cycle is one visit.
Lu-177 PSMA-617
Adults with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed despite standard hormone therapy and (usually) at least one line of chemotherapy or novel hormonal agent.
How you're selected
Selected using a Ga-68 PSMA PET/CT scan — if your prostate-cancer sites light up on that scan, the therapeutic Lu-177-labelled version can treat them.
Typical course
Typically 4 to 6 cycles, 6 weeks apart. Each cycle is one visit.
The treatment day, step by step
From arrival to going home — usually half a day
- 1
Blood tests + review
A few days before treatment you will have blood tests to check kidney function, liver function, blood counts and (for DOTATATE) chromogranin A. If any value is out of range, the team may reduce the dose or reschedule. The morning of the treatment your team confirms all the pre-treatment steps are in place.
- 2
IV cannula + hydration
A cannula is placed in your arm. For DOTATATE therapy, a slow infusion of amino acids (arginine and lysine) begins 30 minutes before the therapy dose — this protects your kidneys, which can otherwise be exposed to a small dose during the treatment. The amino-acid infusion sometimes causes nausea; the team will give you anti-nausea medicine to prevent this.
- 3
The Lu-177 infusion
The Lu-177 medicine itself is infused over about 30 minutes. You will not feel anything unusual during the infusion — no heat, no pain, no immediate side effects. The amino-acid infusion continues alongside for DOTATATE therapy (usually 4 hours total).
- 4
Post-treatment observation
You will rest in the therapy suite for one to a few hours after the infusion ends while the team checks your dose rate (how much radiation you are still emitting) and confirms you feel well. Some centres take a whole-body scan a few hours or the next day to see where the medicine has gone — this scan is important for planning your next cycle.
- 5
Going home + follow-up
Most patients go home the same day. You will receive written radiation-safety instructions (see below) and a follow-up appointment. You will typically not need to return until the next cycle 6 to 8 weeks later, unless side effects appear.
How to prepare
The days before each cycle
Bring your reports
The referring oncologist's letter, your Ga-68 PET/CT scan reports, recent blood tests, and a full list of medicines you take (including supplements and traditional remedies).
Medicines to discuss
Some medicines can reduce how well Lu-177 therapy works — long-acting somatostatin analogues (octreotide, lanreotide) for DOTATATE therapy usually need to be held for 4–6 weeks before, and short-acting octreotide held for 24 hours. Some hormonal / diuretic medicines may also need adjustment. Do not stop any medicine on your own — bring the list and let the team decide.
Hydration
Drink at least 1.5–2 litres of water in the 24 hours before your treatment and continue for 3–4 days afterwards. Well-hydrated kidneys clear the medicine faster and are better protected.
Bathroom access at home
For 24–48 hours after treatment your urine will carry small amounts of Lu-177. Ideally have a bathroom you can use alone (and flush twice) during that period. Sit down to urinate to avoid splashes.
Companion + travel
Bring someone with you but avoid pregnant partners and young children accompanying you into the therapy suite. You can travel home by any means; long international flights within the first few days may set off airport radiation detectors — carry your therapy card.
A comfortable day
Wear loose comfortable clothing. Bring a book, phone charger, snacks and drinking water — the amino-acid infusion for DOTATATE takes 4 hours, and the day involves a lot of sitting.
Radiation-safety after each cycle
Protecting your family for the first week
You will be a source of low-level radiation for a few days after each cycle. The medicine works by delivering radiation from inside — that same radiation reaches a very short distance beyond your body, so anyone close to you gets a very small dose. Following these steps for the first 3 to 7 days after each cycle keeps that dose to your family below any medical limit. Your treating team will give you the specific number of days that apply to your dose; the guidance below is the general template.
Time near family (first 3–7 days)
Keep a small distance from family for the first few days — the more distance and the less time, the lower their exposure. Sleep in a separate bed for 3–7 days if possible (your team will give you the exact number based on the dose delivered). Avoid prolonged close contact (long hugs, holding a child on your lap) for the same period.
Pregnant women and young children
Stay farther away from pregnant women and children under 2 years for 7 days after treatment. Do not have pregnant visitors to your bedroom for that period. If you are a caregiver for a small child and there is no alternative, tell the team before treatment — they will give you specific advice.
Bathroom care
Sit down to urinate for 3–4 days to avoid splashes. Flush twice. Wash your hands thoroughly after each use. If you spill urine on your skin or clothing, wash the skin with soap and water and launder the clothing separately once.
Sweat + saliva + fluids
Sweat and saliva carry only very small amounts of Lu-177 but the same "wash hands, launder separately" rule applies for 3–4 days. Do not share drinks, cutlery or towels for that period.
Intimate contact
Avoid intimate contact (kissing, sexual activity) for 7 days after treatment. Both men and women should use effective contraception during the treatment course and for at least 6 months after the final cycle — Lu-177 therapy can affect fertility temporarily.
Airports + workplace
You may set off sensitive radiation detectors (at airports, courtrooms, some hospitals) for up to 3 months after treatment even though the dose is very low. Your team will give you a therapy card / letter — carry it. Return to work when you feel able, usually within a few days; you are not restricted from public transport or public spaces.
Call the team if…
You develop persistent nausea or vomiting that does not settle with anti-nausea medicine, high fever above 38.5 °C, bruising or bleeding without cause, severe fatigue, reduced urine output, or new severe pain. Your team will give you a 24-hour contact number — use it. Most side effects are mild and resolve within a week.
Not all Lu-177 is the same
"No-carrier-added" quality matters for how well the treatment works
There are two grades of Lu-177 used in radionuclide therapy: "carrier-added" (c.a.) and "no-carrier-added" (n.c.a.). This is a technical distinction but it affects the quality of your treatment — worth asking about.
Higher "targeting purity"
With no-carrier-added Lu-177, essentially every molecule of DOTATATE or PSMA-617 in the injection is carrying an active radioactive lutetium atom. With carrier-added grade, most of the DOTATATE / PSMA molecules carry non-radioactive lutetium instead — they still bind to your cancer cells but deliver no treatment dose, and they compete with the useful molecules for the same receptors on the tumour surface.
Lower ligand mass per injection
n.c.a. quality allows the same therapeutic radioactivity to be delivered with much less peptide mass injected — the physical amount of DOTATATE / PSMA-617 your body receives is smaller. This matters for keeping the injection tolerable across multiple cycles and for reducing any unrelated protein-related side effect.
The technical specification and peer-reviewed evidence on carrier-added vs no-carrier-added Lu-177 quality is on theclinical evidence libraryfor your treating team to review.
Worth knowing · Verification
Not every Lu-177 sold as "n.c.a." actually meets the n.c.a. specification
No-carrier-added and carrier-added Lu-177 are dispensed in similar-looking vials and administered the same way — you cannot tell them apart by looking, and the printed label alone is not proof. In the Indian market, some batches sold under the "n.c.a." label are in fact carrier-added product. Whether the difference matters clinically depends on your specific indication and dose, but if your team plans the treatment around n.c.a.-grade material, the grade needs to be verifiable — not assumed.
The Certificate of Analysis is the only defensible check
Every Lu-177 shipment carries a Certificate of Analysis (CoA) — a per-lot document from the production laboratory. Three fields on the CoA distinguish genuine n.c.a. from carrier-added material. If the grade matters to your treatment, your nuclear-medicine physician, radiopharmacist or radiation-safety officer can verify each field before your dose is dispensed:
1 · Specific activity
Reported as GBq per milligram (or mCi/µg) at a stated reference date. Genuine n.c.a. Lu-177 typically reports at least 500 GBq/mgat reference — many suppliers spec well above 3 000 GBq/mg. Carrier-added Lu-177 typically reports around 15–40 GBq/mg— an order of magnitude or more below the n.c.a. floor. This single number on the CoA is the clearest distinguishing check.
2 · Production method
Genuine n.c.a. Lu-177 is produced by chemical separation from an enriched Yb-176 target (the Lu-177 is separated from the ytterbium after neutron activation). Carrier-added Lu-177 is produced by direct neutron activation of a natural or enriched Lu-176 target. The CoA states which production route was used.
3 · Lu-177m content
Lu-177m is a long-lived (160-day half-life) contaminant that changes the waste-disposal timeline of the treatment. Genuine n.c.a. has tightly controlled Lu-177m content; carrier-added routes tend to carry more. The CoA lists this as % of total activity at reference date.
Ask your care team to share the CoA of your specific lot if you want to see the numbers yourself. Reputable clinical centres are used to this request — the CoA is a standard document that ships with every batch, not privileged information. If the specific-activity number on the CoA is well below 500 GBq/mg despite the label saying "n.c.a.", it is worth a conversation with the treating team about what was actually supplied.
This is educational — the grade decision is a clinical + procurement decision for the treating centre. But the CoA is checkable, and the specific-activity number is unambiguous.
Questions to ask your care team
Eight questions worth writing down
Take this list to your pre-treatment consultation. You will be given a lot of information at once — a written list of the questions that matter to you helps make sure nothing slips through.
- ❓Am I a candidate for Lu-177 therapy based on my Ga-68 PET scan? Which of my tumour sites show high uptake?
- ❓How many cycles are you planning, and how far apart? When is the first cycle scheduled?
- ❓What is the quality grade of the Lu-177 the department uses — is it no-carrier-added (n.c.a.)?
- ❓Can you share the Certificate of Analysis for the specific lot I will receive? What is the specific-activity number in GBq per milligram?
- ❓Which of my current medicines need to be stopped before treatment, and for how long?
- ❓What are the specific radiation-safety instructions for my family — how many days, how much distance, what about children in the household?
- ❓What are the expected side effects for me specifically — and what is the number to call outside clinic hours?
- ❓What is the plan for follow-up scans and blood tests between cycles?
Availability across India
Ask your nuclear-medicine team about the quality of Lu-177 they use
No-carrier-added Lu-177 is supplied across India by Saxsons Group. If your treating centre already runs a Lu-177 theranostic programme, they likely already have access to n.c.a. quality material; if the centre is starting a programme, the supply chain is in place. Which Lu-177 grade is used is a clinical decision for your treating team; this page exists so you can ask an informed question about a technical detail that does affect the quality of your treatment.
This page is educational and does not constitute medical advice. Always follow the instructions of your treating nuclear-medicine team and oncologist.